FDA approves trial comparing canaloplasty and SLT

Sight Sciences will evaluate the safety and efficacy of ab interno canaloplasty using the Visco360 viscosurgical system compared with selective laser trabeculoplasty (SLT) for reducing IOP in primary open-angle glaucoma.

"I have performed hundreds of ab externo canaloplasties over the years with excellent results. I am excited to participate in the Visco360 study to characterize the safety and effectiveness of ab interno canaloplasty for patients with primary open angle glaucoma who do not need a combined procedure with cataract surgery,” said Dr. Steven Sarkisian, professor of ophthalmology at the Dean McGee Eye Institute at the University of Oklahoma and a principal investigator in the Visco360 study. “I believe that glaucoma specialists, comprehensive ophthalmologists, and any anterior segment surgeons will find this familiar ab interno approach to canaloplasty extremely useful for the care of their mild to moderate glaucoma patients."

The Visco360 viscosurgical system is a general purpose instrument that facilitates the delivery of small, controlled volumes of viscoelastic fluid anywhere in the anterior segment. The device is a fully integrated, single-handed, single-use device that combines a custom access cannula, a soft and flexible microcatheter with an atraumatic tip, an internal infusion pump and viscoelastic reservoir, and a control wheel that advances and retracts the microcatheter.